Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7125917 | 1.00 | JAK2 (0.36) | JAK2JAK1FLT3AURKBALDH1A1 | |
| SCHEMBL7123457 | 1.00 | JAK2 (0.36) | JAK2JAK1FLT3AURKBALDH1A1 | |
| SCHEMBL27416122 | 1.00 | JAK2 (0.36) | JAK2JAK1FLT3AURKBALDH1A1 | |
| SCHEMBL13945596 | 1.00 | JAK2 (0.36) | JAK2JAK1FLT3AURKBALDH1A1 | |
| SCHEMBL7125915 | 1.00 | JAK2 (0.36) | JAK2JAK1FLT3AURKBALDH1A1 | |
| SCHEMBL22262566 | 0.90 | JAK2 (0.35) | JAK2JAK1FLT3AURKBALDH1A1 | |
| SCHEMBL23489324 | 0.88 | JAK2 (0.35) | JAK2JAK1FLT3AURKBBCHE | |
| SCHEMBL17104749 | 0.88 | JAK2 (0.33) | JAK2JAK1FLT3AURKBBCHE | |
| SCHEMBL23489317 | 0.88 | JAK2 (0.35) | JAK2JAK1FLT3AURKBBCHE | |
| SCHEMBL23552541 | 0.85 | BCHE (0.35) | JAK2JAK1FLT3AURKBBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SENDA BIOSCIENCES INC (US) | 2022-02-10 | — | — | US | disclosed |
| EP-3891751-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020118238-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041641-A1 | QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION | SLC10A2, SLC10A1, BCAT2 | JAK2 2779/4885JAK1 3499/4885FLT3 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.